Minimally invasive treatment of benign prostate enlargement

Series
Men’s health
Status
Published
Date
Number of report
081

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of minimally invasive treatment of benign prostate enlargement. The analysis will cover hospital, day case and outpatient settings.

The following procedures will be considered under the scope of analysis:

  • Transurethral microwave thermotherapy (TUMT)
  • Holmium laser enucleation of the prostate (HoLEP)
  • Photoselective vaporization of the prostate
  • High intensity focused ultrasound (HIFU)
  • Prostatic Urethral Lift
  • Transurethral resection of the prostate (TURP) – as comparator.

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers devices of minimally invasive treatments of benign prostate enlargement include:

  • Allium Medical (TPS)
  • Biolitec AG (Leonardo)
  • Boston Scientific (GreenLight XPS, Rezum, GreenLight XPS, Moxy, Lumenis Pulse, GreenLight HPS)
  • HIFU: Sonacare Medical (Sonablate), EDAP TMS (Ablatherm, Focal One)
  • KARL STORZ (Endoscopic Enucleation and Morcellation)
  • LISA Laser (RevoLix 200, RevoLix Duo)
  • Lumenis (Moses Pluse, VersaPulse PowerSuite)
  • Pnn Medical (Memokath)
  • PROCEPT BioRobotics (AquaBeam)
  • Richard Wolf (Bipolar enucleation electrode, Shark, Piranha)
  • SRS Medical (Spanner)
  • Teleflex (UroLift)
  • Olympus (Plasma)
  • UroTech (Prostatron, GreenLight PV)
  • Urologix (Prostiva RF, Cooled ThermoTherapy)

Table of content is not available at the moment. Report is still ongoing.

16

Oct 2019

In September 2019, Regional Methods Council of South East healthcare region released a report where compared the prostate artery embolization (PAE) for benign prostatic hyperplasia with the transurethral resection of the prostate (TURP). It was outlined that costs and the need for blood transfusions for PAE are lower than for TURP. The use of registries for follow-up of patients and registration of side effects is strongly recommended.

Read more

16

Sep 2019

The report presents a summary of the reimbursement situation for use of minimally invasive treatment of benign prostate enlargement in Europe. The following procedures will be considered under the scope of analysis: transurethral microwave thermotherapy (TUMT), Holmium laser enucleation of the prostate (HoLEP), photoselective vaporization of the prostate, high intensity focused ultrasound (HIFU), Urolift, transurethral resection of the prostate (TURP) as a comparator. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

11

Apr 2019

On March 15, 2019, the Swiss Medical Board published two appraisal reports: “Robot-assisted laparoscopic surgery versus open surgery for radical prostatectomy” and “Robot-assisted laparoscopic surgery versus conventional laparoscopic surgery for simple or radical hysterectomy.”

Read more

28

Feb 2019

In January 2019, the National Institute for Health and Care Excellence (NICE) published six new interventional procedure guidance, three medical technologies guidance, and three new MedTech innovation briefings for liver function capacity test, a functional electrical stimulation (FES) integrated cycling system used to start muscle contraction to stimulate trunk and limb muscles in people with spinal cord injury, laser shoe attachment used as a walking aid and is designed to help prevent freezing of gait in people with Parkinson's disease.

Read more

14

Jan 2019

In January 2019, the Danish Health Authority (Sundhedsstyrelsen) released a new national clinical guideline, which focuses on the choice between radical prostatectomy and the option of active monitoring of prostate cancer.

Read more

24

Aug 2017

G-BA started review process for number of procedures for treatment of benign prostate enlargement in 2009. After publication of the results of rapid health technology assessment by the Institute for Quality and Efficiency in Health Care (IQWiG), G-BA was able to come to the conclusion in June 2017 about efficacy and safety of the thulium laser resection of prostate are well documented and procedure can be covered within statutory health insurance in Germany.

Read more

03

Jul 2017

French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of 8 medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS). They include coronary stents, portable oxygen concentrators, Urolift device, spinal ganglion stimulator and insulin pumps.

Read more

20

Jun 2017

In May 2017, CNEDiMTS at the National Authority for Health (HAS) issued positive assessment of Urolift for add-on reimbursement via LPPR list. Added value was found to be minor in comparison with transurethral resection of prostate (TURP). This assessment provides better results compared to the earlier one in January 2017. Add-on reimbursement might be established within about one year period.

Read more
(we accept only company emails)